Immunodeficiency 18 (IMD18) Cell Models for Research

Immunodeficiency 18 (IMD18) is a rare primary immunodeficiency disorder caused by mutations in the CD3E gene. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. Patients typically present in infancy with severe recurrent infections, autoimmune manifestations, and failure to thrive. Without early hematopoietic stem cell transplantation, the condition is often fatal. The disease is characterized by a profound T-cell deficiency, leading to combined immunodeficiency. According to the WHO, primary immunodeficiencies are underdiagnosed, and IMD18 represents a critical area for research due to its severity and the potential for gene therapy.

IMD18 is an ideal model for studying T-cell development, T-cell receptor (TCR) signaling, and immune tolerance. The CD3E gene encodes the epsilon subunit of the TCR-CD3 complex, which is essential for TCR expression and signal transduction. Research on IMD18 can provide insights into fundamental mechanisms of immune function and offer a platform for testing novel immunotherapies. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and the European Society for Immunodeficiencies (ESID), provide clinical and genetic data that facilitate research. Open questions include the molecular basis of variable clinical severity and the development of targeted therapies.

While IMD18 is not a cancer, the molecular pathways involved in T-cell signaling are also implicated in hematological malignancies. The TCR signaling pathway is critical for T-cell activation and proliferation. Key steps include:

1. Antigen recognition by the TCR-CD3 complex.

2. Recruitment of Lck to the CD3 cytoplasmic domains.

3. Phosphorylation of ITAMs (immunoreceptor tyrosine-based activation motifs) on CD3 subunits.

4. Activation of ZAP-70 and downstream signaling cascades (e.g., MAPK, NF-κB, NFAT).

Dysregulation of these pathways can lead to uncontrolled T-cell proliferation and leukemia/lymphoma. Therefore, IMD18 models are valuable for studying TCR signaling and its oncogenic potential.

Data from ClinVar and COSMIC indicate that CD3E mutations are the primary cause of IMD18, with over 20 pathogenic variants reported.

The loss of CD3ε disrupts the TCR signaling network, leading to:

• • Impaired T-cell development in the thymus.
• • Defective T-cell activation and proliferation.
• • Reduced cytokine production (e.g., IL-2, IFN-γ).
• • Altered calcium flux and NFAT activation.

Key nodes in the network include:

• • TCR-CD3 complex
• • Lck, Fyn
• • ZAP-70
• • LAT, SLP-76
• • PLCγ1, PKCθ
• • NF-κB, NFAT, AP-1

Organoids, such as thymic organoids, can be generated from patient-derived induced pluripotent stem cells (iPSCs) to model T-cell development. These models are valuable for studying the effects of CD3E mutations in a three-dimensional context.

Animal models for IMD18 include:

• • CD3E knockout mice: These mice exhibit a severe block in T-cell development, mimicking the human phenotype.
• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient immune cells can be used to study the disease.
• • Genetically engineered mouse models (GEMM): Conditional knockouts allow temporal and tissue-specific deletion of CD3E.
• • Induced models: CRISPR-mediated knockout in mouse embryos to generate germline mutations.

CRISPR-based gene editing allows the creation of isogenic cell lines with specific CD3E mutations. For example:

• • CD3E knockout cell lines: Generated by introducing frameshift mutations via CRISPR-Cas9, resulting in complete loss of CD3ε expression.
• • CD3E point-mutation knock-in lines: Introduce specific patient mutations (e.g., p.Arg90Ter) to study their functional impact.

These models are commercially available and sequence-verified, providing researchers with reliable tools to study the molecular consequences of CD3E mutations. They are essential for drug screening and functional genomics.

Gene-edited cell lines are used to validate the function of CD3E and other genes in T-cell signaling. For example:

• • Knockout of CD3E in Jurkat cells abolishes TCR-mediated activation, confirming its essential role.
• • Knock-in of a specific mutation can reveal its impact on protein stability and signaling.
• • CRISPR screens can identify modifiers of CD3E function, providing new therapeutic targets.

Isogenic pairs (wild-type vs. CD3E knockout) are used to screen for drugs that can bypass the signaling defect. For instance:

• • Compounds that activate downstream signaling (e.g., PMA/ionomycin) can be tested for their ability to restore T-cell activation.
• • Resistance mechanisms to immunomodulatory drugs can be studied by comparing drug responses in wild-type and knockout cells.

CRISPR synthetic lethality screens can identify genes that are essential in CD3E-deficient cells but not in wild-type cells. These genes may serve as biomarkers or therapeutic targets. For example, targeting a synthetic lethal partner could selectively kill defective T cells in autoimmune contexts.